The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of a taxane mRNA-based profile in neoadjuvant therapy across I-SPY2 investigational arms.
 
Jacob Niklassen
Employment - Aida Oncology ApS
Patents, Royalties, Other Intellectual Property - A Taxane gene expression response predictor (Inst)
 
Jan Nart
Employment - Aida Oncology
Stock and Other Ownership Interests - Novo Nordisk
Patents, Royalties, Other Intellectual Property - Biomarkers to predict anti-cancer drug response.; Biomarkers to predict anti-cancer drug response.
Travel, Accommodations, Expenses - Aida Oncology
 
Beatrice Hahn
Employment - Aida Oncology Aps
Patents, Royalties, Other Intellectual Property - Aida Oncology Aps (Inst)
 
Ida Buhl
Employment - Aida Oncology
Leadership - Aida Oncology
Stock and Other Ownership Interests - Aida Oncology
Patents, Royalties, Other Intellectual Property - Aida Oncology
 
Peter Jensen
Employment - Aida Oncology; CHOSA Oncology; Medical Prognosis Institute; Oncology Venture
Leadership - Aida Oncology; CHOSA Oncology
Stock and Other Ownership Interests - Aida Oncology; CHOSA Oncology
 
Ulla Buhl
Employment - AIDA Oncology ApS; AIDA Oncology ApS (I); CHOSA Oncology AB; CHOSA Oncology AB (I)
Leadership - AIDA Oncology ApS; AIDA Oncology ApS (I); CHOSA Oncology AB; CHOSA Oncology AB (I)
Stock and Other Ownership Interests - CHOSA Oncology AB
Patents, Royalties, Other Intellectual Property - Patets for biomarkers for chemotherapeutic drugs
 
Tobias Berg
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst)
 
Bent Ejlertsen
Consulting or Advisory Role - Lilly
Research Funding - AstraZeneca (Inst); Daiichi Sankyo Europe GmbH (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Europe GmbH; MSD; Roche
 
Joyce O'Shaughnessy
Honoraria - AADi; Agendia; Amgen; Aptitude Health; AstraZeneca; BioNTech; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Oncology; DualityBio; Eisai; Ellipses Pharma; Exact Sciences; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; HiberCell; Jazz Pharmaceuticals; Johnson & Johnson; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Sanofi; Seagen; Stemline Therapeutics; Summit Therapeutics; Tempus; Tersera
Consulting or Advisory Role - AADi; Agendia; Amgen; Aptitude Health; AstraZeneca; BioNTech; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Oncology; DualityBio; Eisai; Ellipses Pharma; Exact Sciences; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; HiberCell; Jazz Pharmaceuticals; Johnson & Johnson; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Sanofi; Seagen; Stemline Therapeutics; Summit Therapeutics; Tempus; Tersera
Travel, Accommodations, Expenses - Aptitude Health; Daiichi Sankyo; DAVA Oncology; Lilly; Merck; Novartis